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Abstract
Purpose
18F-Fluoride PET/CT is a relatively undervalued
diagnostic test to measure bone metabolism in bone
diseases. Hyperostosis cranialis interna (HCI) is a (hered-
itary) bone disease characterised by endosteal hyperostosis
and osteosclerosis of the skull and the skull base. Bone
overgrowth causes entrapment and dysfunction of several
cranial nerves. The aim of this study is to compare
standardised uptake values (SUVs) at different sites in
order to quantify bone metabolism in the affected anatom-
ical regions in HCI patients.
Methods Nine affected family members, seven non-affected
family members and nine non-HCI non-family members
underwent
18F-fluoride PET/CT scans. SUVs were system-
atically measured in the different regions of interest: frontal
bone, sphenoid bone, petrous bone and clivus. Moreover,
the average
18F-fluoride uptake in the entire skull was
measured by assessing the uptake in axial slides. Visual
assessment of the PET scans of affected individuals was
performed to discover the process of disturbed bone
metabolism in HCI.
Results
18F-Fluoride uptake is statistically significantly
higher in the sphenoid bone and clivus regions of affected
family members. Visual assessment of the scans of HCI
patients is relevant in detecting disease severity and the
pattern of disturbed bone metabolism throughout life.
Conclusion
18F-Fluoride PET/CT is useful in quantifying
the metabolic activity in HCI and provides information
about the process of disturbed bone metabolism in this
specific disorder. Limitations are a narrow window between
normal and pathological activity and the influence of age.
This study emphasises that
18F-fluoride PET/CT may also
be a promising diagnostic tool for other metabolic bone
disorders, even those with an indolent course.
Keywords Bone dysplasias.Fluorine.Hyperostosis.
Osteosclerosis.Positron emission tomography
Introduction
Hyperostosis cranialis interna (HCI) (Online Mendelian
Inheritance in Man 144755) is a disorder which was first
described in 1990 and is characterised by hyperostosis and
osteosclerosis of the calvaria and skull base (Fig. 1)[ 1].
This leads to a narrowing of cranial nerve foramina causing
entrapment and dysfunction of cranial nerves I, II, V, VII
and VIII. Facial palsy and vestibulocochlear dysfunction
occur at a young age, mainly in the second and third
decades. Smell and vision impairment and trigeminal
neuralgia may occur later. It is a hereditary disorder that,
to date, has been diagnosed in three related Dutch families
only [2]. Besides HCI, numerous bone dysplasias with skull
base and calvarial hyperostosis and osteosclerosis exist.
Van Buchem disease [3, 4], Camurati-Engelmann disease
[5] and sclerosteosis [6] are examples of similar disorders
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and/or diaphyseal involvement. An overview of different
(genetic) skeletal disorders is provided by the International
Skeletal Dysplasia Society [7]. HCI is the only bone
disorder affecting solely the skull.
The diagnosis of HCI is suspected by family history and
physical examination and confirmed by computed tomog-
raphy (CT). Analysis of sequential CT scans of affected
individuals gives the impression that the frontal bone and
the (medial part of the) petrous bone are affected first, in
the late first or early second decade. This process seems to
continue until the age of 40. In the greater sphenoid wing
hyperdense areas are visible in adolescence (comparable to
the frontal bone region); however, usually obvious hyper-
ostosis starts later (third decade) and progresses until later
in life. Findings for the parietal bone are similar,
becoming pathologically dense and hyperostotic from
the third decade on. The anterior and middle skull base
are affected, whereas the occipital region is hardly
involved (Fig. 1). In HCI there is no involvement of the
tubular bones. An additional dynamic bone imaging
technique,
18F-fluoride positron emission tomography
(PET), could provide valuable information in analysing
and quantifying bone metabolism.
18F-Fluoride was described as a tracer for bone imaging
by Blau et al. in 1962 and 1972 (conventional scintigra-
phy), but fell into disuse [8, 9]. In 1992, PET scans using
18F-fluoride were introduced to quantify bone formation
[10]. Compared to conventional gamma cameras including
single photon emission computed tomography (SPECT),
PET scans have higher spatial resolution and a greater
sensitivity than gamma cameras and offer direct quantifi-
cation of bone imaging studies. Grant et al. reviewed the
available studies about clinical utility of
18F-fluoride PET/
CT scanning [11]. Although the specific bone uptake is
similar for both radionuclides, there is less plasma
protein binding of
18F-fluoride [12] and the half-life is
considerably shorter (110 min and 6 h, respectively).
18F-
Fluoride PET scanning offers shorter study times and is
therefore more convenient for patient and physician. The
effective dose of
18F-fluoride PET is somewhat higher
compared to
99mTc bone scanning (4.0 versus 3.0 mSv,
respectively) [11].
18F-Fluoride PET is more accurate than
planar imaging or SPECT with
99mTc-methylene
diphosphonate (MDP) for the detection of small focal
lesions, such as metastases [13]. Because of its easier
quantification capabilities,
18F-fluoride is very useful for
t h ea s s e s s m e n to fb o n em e t a b o l i s m .
With
18F-fluoride PET differences in bone metabolism
between affected HCI patients, unaffected family members
and unaffected control subjects are visualised and quanti-
fied in different anatomical subsites. The aims of this study
are (1) to provide additional information about the early
stage of HCI and (2) to monitor disease activity at different
anatomical subsites and predict disease progression which
can be important for treatment decisions.
a
b
c
frontal bone
anterior skull base
clivus
d
1
2
3 4
5
Fig. 1 CT images of affected
individuals. a Coronal
reconstruction of the middle
skull base with near-total
obliteration of the internal audi-
tory canal (oval), endosteally
thickened parietal area (arrow).
Note the subcutaneous wires of
auditory brainstem implantation
device (left). b Paramedian
sagittal reconstruction. Frontal
bone and anterior skull base
are affected. Vertebral column,
nasal bones and clivus show no
hyperostosis. c Axial image
of the temporoparietal area
revealing exorbitant endosteal
hyperostosis. d Axial overview
of a 24-year-old affected
woman: 1 right frontal sinus, 2
sphenoid sinus, 3 sphenofrontal
suture, 4 sphenoparietal suture,
5 apex of the left petrous bone.
Arrows apposition of excessive
endosteal bone. Oval normal
configuration of outer cortex.
Square sclerotic greater
sphenoid wing
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Subjects
The 3 related families have common progenitors and
consist of 31 individuals (Fig. 2), 3 of whom are deceased.
One individual did not participate because of a psychiatric
condition at the time of the study. A total of 11 children (all
under 5 years old) did not undergo a PET/CT scan because
of their age. The remaining 16 were included: 9 family
members with proven CT abnormalities (group 1) and 7
family members without CT abnormalities (group 2).
The control group consisted of nine patients (group 3),
mainly examined for orthopaedic diagnostic reasons (with-
out symptoms or a disease history in the head and neck
region). The Medical Ethics Committee of the Maastricht
University Medical Centre approved the research protocol
(document number MUMC 09-4-050.4/PL) and all patients
gave their written informed consent. All individuals
underwent an
18F-fluoride PET/CT scan between August
2007 and November 2008.
PET imaging
The average
18F-fluoride activity administered to all
patients was approximately 200 MBq (effective dose
5.4 mSv). PET/CT scans of the head and upper torso were
made after 1 h, acquiring data for 4 min per bed position. A
PET/CTscanner with a 64-slice CTcomponent (Gemini TF,
Philips, Best, The Netherlands) was used. In all cases, low-
dose CT (30 mAs, 0.5 mSv) was performed. If needed for
diagnostic reasons, high-resolution CT was performed as
well. Using the standard Philips time-of-flight ordered
subsets expectation maximisation reconstruction (33 subsets,
3 iterations), images corrected for random events, scattered
radiation and attenuation were obtained. The PET matrix size
was 144, resulting in a voxel size of 4×4×4 mm
3.
Visual assessment
All PET scans were visually analysed and compared to the
complementary CT scans with Philips Extended Brilliance™
Workspace in order to assess their clinical value. This
programme is used for assessment of PET/CT scans in
everyday clinical practice at our institute. The PETscans were
fused with the 4-mm CT scans and depicted in “thermal”
colour scale setting and compared to high-resolution CTscans
of the skull base. The areas of interest were analysed by
displaying identical settings: the low-level filter was set at
standardiseduptakevalue(SUV)=1.3andtheupper-levelfilter
at SUV=12.0. Additionally, hot spots were detected by visual
scoringofthescansandbyassessingtheSUVmax of each slice.
Standardised measurements
The scans were analysed using PMOD 2.95 (PMOD
Technologies Ltd., Zurich, Switzerland). A region of
interest (ROI) with a radius of 5 mm was placed in the
axial plane around the maximal activity in different
anatomical regions: greater sphenoid wing (left and right),
frontal bone (cranial to orbital or frontal sinus), apex of the
petrous bone (left and right) and clivus. Initially in each of
these anatomical regions a manually drawn ROI was
created including the entire region. This was repeated for
all planes comprising the region concerned and in these
ROIs the point of maximal activity was assessed. Conse-
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Fig. 2 Pedigree of the affected HCI families
886 Eur J Nucl Med Mol Imaging (2011) 38:884–893quently, the coordinates of these points of maximal activity
were used as the centre of the smaller, circular ROIs with a
radius of 5 mm. The data of this ROI were used for
calculation of the SUV. For all anatomical subsites the
SUVmean and SUVmax were calculated.
The corpus of the third cervical vertebra was chosen as
internalcontrolsite.Intheareascanned,thevertebrae,clavicles
and the cheek bones are the only bony structures clearly not
affected in HCI patients. The vertebrae were considered the
most appropriate because of their size. None of the scanned
individuals, regardless of group, had neck conditions.
Total uptake of the skull was also assessed. ROIs were
created in the axial plane with the inside (A) and outside
(B) boundaries of the skull (Fig. 3). The uptake in the bone
was drawn up by subtracting the data of A from B. Next we
calculated the average uptake in the entire skull. To
accomplish this the average uptakes in all planes (from
the skull base to the vertex) were added and divided by the
total volume (slice thickness of one region equals 4 mm).
With these data the SUVs of the ROIs were calculated
using the following formula:
SUV g=mL ½  ¼
TissueActivityðkBq=mLÞ
ActivityInjectedDoseðkBqÞ BodyWeightðgÞ =
Statistical analysis
Sample means, standard deviations and the range of
SUVmean and SUVmax were calculated per group.
Kolmogorov-Smirnov tests were performed for all contin-
uous metric data to test for normality. Frequencies and
percentages are given for categorical data.
Boththe parametricanalysisofvariance(ANOVA)andthe
nonparametric Kruskal-Wallis overall tests were performed to
examine differences between the three groups. To compare
HCI patients and non-HCI family members on the one hand
and HCI patients and control subjects on the other hand, the
parametric t test and the Mann-Whitney test were used.
All data were analysed with SPSS PC version 16; p values
less than 0.05 were considered as denoting statistical
significance.
Results
In group 1, nine (affected) individuals were included (six
women and three men, mean age 32, range 11–68). Group 2
consisted of seven non-HCI family members (five women
and two men, mean age 29, range 14–40). A total of nine
control subjects (group 3) were scanned (five women and
four men, mean age 60, range 42–75).
Visual assessment
General findings
Skull sutures show enhanced uptake in all individuals, both
affected as well as unaffected. In unaffected individuals
minor physiological irregularities are sometimes observed
at the endosteal side of the frontal bone area on CT as well.
However, other parts of the cranial vault are always
smoothly delineated in unaffected individuals. Hot spots
unrelated to HCI (Fig. 4) comprise among others areas of
embryologically fused bone (i.e. clivus, sphenoid wing), the
nasal bones and the temporomandibular joint.
Hot spots and other interesting findings related to HCI are
displayed in Fig. 5. The majority of the hot spots (besides
those found in the standardised measurement areas) are
found in three different regions: the cranial part of the frontal
bone, the sphenofrontal suture and the occipital suture.
In HCI the first abnormal findings are seen in the frontal
bone (Fig. 6). Generally, the endosteal abnormalities of the
affected calvarial bones (frontal and parietal) are found at
the base of the endosteal border of the hyperostotic region
(Fig. 5c–f and Fig. 6).
Frontal bone area
The frontal bone area is a pathognomonic area in visual
assessment. In young affected individuals (late first, early
second decade), a typical enhancement pattern is observed
(Fig. 6). First subtle sclerotic changes of the skull are
Fig. 3 Measuring the total uptake of the skull using PMOD 2.95: A
(inside) = blue line, B (outside) = green line; total skull uptake per
slice was calculated by subtracting the data of A from B (B−A).
Results of all planes together (up from the skull base to the vertex)
were added resulting in the total uptake of the bone
Eur J Nucl Med Mol Imaging (2011) 38:884–893 887observed (CT). When abnormalities on CT are hardly
visible, frontal endosteal activity is detected (Fig. 6a). Hot
spots are seen at sclerotic sites and diffusely enhanced areas
are seen at (CT) hypodense hyperostotic areas. Frontal bone
uptake gradually becomes more explicit during the second
decade and can become fulminant (Fig. 6b). As soon as an
endosteal border of bone apposition is visible, the abnormal
activity is observed at the endosteal side of the diploë (bone
marrow) and not centrally in the endosteal border (Fig. 6b,
c). Later (>30 years), frontal bone activity gradually
decreases and the process of hyperostosis extinguishes
(Fig. 6d, e).
Petrous bone area
A varying inter-individual degree of pneumatisation and
increasing pneumatisation throughout life make it difficult
to precisely quantify bone metabolism in this region.
Therefore, visual assessment of the scans of HCI patients is
important in that it shows a typical enhancement pattern.
Affected adolescents and patients in their 20s have diffuse
enhancement of the petrous bone apex in the region of the
internal auditory canal (Fig. 7a, b), representing active
osteosclerosis and hyperostosis of the medial part of the
petrous bone (the region around the internal auditory canal
containing the facial and vestibulocochlear nerves). From the
age of 30 onward the typical endosteal enhancement pattern
can be recongnised as earlier in the frontal area (Fig. 7c, d).
There is a diffuse hyperactive border at both the anterior and
posterior side of the petrous bone, the latter vanishing with
increasing age (Fig. 7e). Throughout life, there is no disease
involvement of the mastoid, middle and inner ear visible
with
18F-fluoride PET, corresponding to the CT findings.
Sphenoid bone and temporal area
Atthesitesoffusionofthegreatwingofthesphenoidboneand
the temporal and frontal bone (sphenopetrosal and spheno-
cd
ab
Fig. 4 Hot spots unrelated to
HCI. a Occipital osteoma cranial
to the foramen magnum. b Hot
spots visible in metabolically
active bone regions. Note the
clivus (arrow), which is a
junction of two bone segments.
The centre of the corpora of the
vertebral column and the
occipital protuberance show
enhanced activity as well.
c Bilateral enhancement of the
labyrinth in a control subject
with cochlear otosclerosis.
d Hot spot at the caput
mandibulae/temporomandibular
joint
888 Eur J Nucl Med Mol Imaging (2011) 38:884–893frontal suture) there is enhancement in both affected as well as
unaffected individuals. No typical pattern is visible in the
abnormalities of the sphenoid bone area. Affected individuals
have more pronounced activity at the surrounding endosteal
part of the greater sphenoid wing. During life, an impressive
endosteal border of additional bone forms at the level of the
greater sphenoid wing and parietal bone, which remains more
active than the sphenoid area in healthy individuals.
Data analysis
The results of the standard measurements for all groups
together are shown in Table 1. Table 2 shows a breakdown
of SUV parameters per group. The average SUV seems to
be higher in group 1 for all locations except for the control
site of the third cervical vertebra.
The average SUV of the complete skull is not signifi-
cantly higher for group 1 (SUV=1.74±0.55) when com-
pared to groups 2 and 3 (1.49±0.21 and 1.44±0.55).
Uptake of
18F-fluoride in the frontal region (SUVmean)i s
higher in the HCI group but no statistical significance is
reached (ANOVA p=0.06, Kruskal-Wallis p=0.14). To
investigate whether the outcomes were dependent on age,
patients above and below the age of 40 were compared and
on average the younger group had a 1.63 higher value, this
difference being just barely statistically significant for the
ANOVA (p=0.049) and not quite for the Kruskal-Wallis
test (p=0.051).
The group average SUVmean in the petrous bone region
is higher in HCI patients as compared to the other groups
(group 1 4.47±1.56 versus group 2 3.93±1.31 and group 3
3.82±0.96), but not statistically significant.
b a c
2nd decade 4th decade 5th decade
f e d
Fig. 5 Hot spots and other
findings in HCI-affected
individuals. a Postoperative
status after optic nerve decom-
pression at the right side in an
affected individual. The oblique
operation tract can still be seen
(oval). Hot spot at the junction
between the greater sphenoid
wing, the frontal bone and the
parietal bone at the left side.
b Hot spot at the symphysis
mandibulae. Typically the
mandibular exostoses (arrow)
do not show enhanced uptake;
the symphysis mandibulae and
the base of the exostoses do
have enhanced uptake. c View
of the whole right axial skull
base of a 39-year-old woman.
Note that the activity is located
at the base of the endosteal
border of the hyperostosis. d–f
Enhanced activity of the parietal
area. Note that the activity is not
located in the endosteal part
solely, but mainly at the base of
the hyperostotic border
Eur J Nucl Med Mol Imaging (2011) 38:884–893 889The clivus and the sphenoid bone regions have
corresponding findings, although the sphenoid area is
affected by HCI and the clivus does not show obvious
hyperostosis. SUVmean in the clivus area is 6.17±1.38 in
group 1, 5.70±1.36 in group 2 and 4.18±1.12 in group 3.
There is a statistical significance between group 1 and
group 3 for both SUVmean and SUVmax (t test p=0.010 and
rank test p=0.009). SUVmean in the sphenoid area is 6.58±
1.62 in group 1, 5.66±1.21 in group 2 and 7.75±2.03 in
group 3. SUVmax values show comparable results. In both
areas age seems to influence the SUV values: group 2
values are positioned in between groups 1 and 3, 1 being
the highest (with youngest average age) and 3 the lowest
(with highest average age). For the sphenoid area a
statistically significant difference between groups 2 and 3
is also found.
In Table 3 the SUV values of the hot spots in HCI
patients are displayed.
Discussion
Technical considerations concerning
18F-fluoride PET/CT
To obtain reproducible outcome measurements several
pharmacokinetic models have been described for
18F-
early 2nd decade 3rd decade 4th decade 5th decade late 2nd decade
de bc a
Fig. 6 a–e Evolution of the disturbed bone metabolism throughout life in HCI patients, as observed in the frontal bone area. Note that the outer
cortex is not abnormal; however, the endosteal border thickens during life and the enhanced activity is found at the base of the hyperostotic border
2nd decade 3rd decade 4th 5   e t a l e d a c e d th decade control early 5th decade
de bf c a
internal 
auditory canal
Fig. 7 a–f Bone metabolic activity of the petrous bone throughout life. There is important enhanced activity in the inner auditory canal region,
corresponding to the facial and vestibulocochlear nerve impingement. Note the absence of enhancement in the control subject (age 29)
890 Eur J Nucl Med Mol Imaging (2011) 38:884–893fluoride PET scans. Hawkins et al. developed a three-
compartment model producing quantitative measurements
for the net uptake of
18F-fluoride into bone [10]. A rate
constant (K) for this uptake can be calculated as a macro-
parameter using the individual rate constants described in the
model obtained by nonlinear regression methods (NLR). This
KNLR provides a tool for measuring the bone turnover that
correlates with biochemical data and bone histomorpho-
metric analyses performed on biopsy samples [14, 15].
However, it requires blood sampling and is therefore not
widely used in clinical practice. Brenner et al. recognised
this and compared the KNLR t ot h em o r ec o m m o n l yu s e d
SUV for semi-quantitative metabolic bone measurements
[16]. They found a strong positive linear correlation that
was highly significant and reproducible. Thus, SUV is not
only more practical and noninvasive but also equally
reliable using
18F-fluoride in PET imaging. Installé et al.
confirmed this after comparing kinetic modelling, SUV
and biochemical markers in monitoring the therapeutic
response in Paget’s disease of bone [17]. This study
confirms the reproducibility of SUV in both unaffected as
well as affected regions.
Standardised measurements of
18F-fluoride uptake in HCI
compared to healthy controls and non-affected family
members
We analysed SUVmax and SUVmean at different anatomical
locations following a structured protocol. Both outcome
measures give comparable results. Statistical power was
limited by the small group sizes. Uptake in the third cervical
vertebra served well as an internal control measurement.
Statistically significant differences were found for various
measurements of the sphenoid bone and clivus. With respect
to the frontal measurement there is clearly a tendency,
however missing power in the statistical analysis.
No significant differences were seen between the groups
concerning the total uptake of the skull. A plausible
explanation is the inclusion of normal bone tissue (the
outer part of the skull) in group 1 within the ROIs,
averaging the scores. Measuring total uptake was time-
consuming and considering the results obtained it does not
appear to be an efficient contribution.
Uptake in the frontal bone showed nearly statistically
significant differences between the study groups. We did
Location Mean SUVmean SD Range Mean SUVmax SD Range
Total uptake 1.56 0.48 0.83–2.62 - - -
Frontal bone 3.67 1.34 1.91–7.50 4.33 1.53 2.33–8.59
Clivus 5.32 1.52 2.49–8.75 6.01 1.77 2.87–9.85
Petrous bone(L&R) 4.09 1.35 1.86–8.27 4.86 1.55 2.09–9.41
Sphenoid bone (L&R) 5.50 1.74 2.80–11.82 6.21 2.01 3.34–13.77
Third cervical vertebra 7.83 2.34 4.09–15.42 8.79 2.65 4.50–17.76
Table 1 Descriptive statistics
for SUVmean and SUVmax for all
locations and all individuals
(n=25)
SD standard deviation, L&R
average of left and right
Table 2 SUVmean and SUVmax for all bone locations for each of the different groups studied (n=25)
Location SUV Group p value
1( n=9), HCI 2 (n=7), family non-HCI 3 (n=9), control ANOVA Kruskal-Wallis
Total uptake Mean 1.74±0.55 1.49±0.21 1.44±0.55 0.412 0.427
Frontal bone Mean 4.51±1.65 3.17±0.87 3.23±0.94 0.060 0.140
max 5.22±1.87 3.78±1.07 3.87±1.13 0.090 0.136
Clivus Mean 6.17±1.38
a, b 5.70±1.36 4.18±1.12
a, b 0.010 0.016
max 7.00±1.61
a, b 6.43±1.70 4.70±1.22
a, b 0.011 0.023
Petrous bone max 4.47±1.56
a 3.93±1.31 3.82±0.96 0.534 0.542
Mean 5.36±1.61 4.67±1.64 4.52±1.19 0.461 0.488
Sphenoid bone Mean 6.58±1.62
a, c 5.66±1.21
b 4.30±0.93
a, b, c 0.004 0.007
max 7.48±1.88
a, c 6.36±1.29
b 4.82±0.97
a, b, c 0.003 0.006
Third cervical vertebra Mean 7.28±1.71 8.18±2.22 8.09±3.05 0.701 0.859
max 8.17±1.93 9.12±2.36 9.16±3.54 0.693 0.873
aSignificantly different, p≤0.01 (Bonferroni t test)
b,
cSignificantly different, p≤0.01 (Mann-Whitney)
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skullcap is unequivocally affected in patients and abnor-
malities develop especially in the first decades. The
findings do encourage our hypothesis that in the frontal
area the process of hyperostosis and osteosclerosis peaks in
the first decades of life and settles down thereafter.
Typically there is no difference between groups 2 and 3,
regardless of the unequal age distribution.
The higher uptake of
18F-fluoride in the petrous bone of
HCI patients does correspond with our expectations,
because the temporal bone is an affected region. Although
the average uptake is higher in group 1 compared to groups
2 and 3, this difference was not statistically significant.
Different degrees of pneumatisation are encountered and
cannot be corrected for in this area. Another explanation,
which becomes clear after visually studying the PET and
CT scans, is the fact that the affected region of the petrous
bone is confined to the endosteal border only.
Uptake in the clivus and sphenoid region are both
significantly higher for the patients compared to the control
group as well as compared to the family non-HCI group.
The mean uptake values of unaffected family members are
obvious between groups 1 and 3 and this demands
explanation. As opposed to other sites, these anatomical
regions have in common that they are active growth centres
(skull base sutures), explaining an increased local fluoride
uptake in bone tissue representing osteoblastic activity [18,
19]. Increasing age is accompanied by a reduction of
standard bone activity in these anatomical areas [20].
Value of visual assessment in HCI
18F-Fluoride PET is a very sensitive imaging technique.
Hot spots are found long after surgical interventions
(mastoidectomy, optic nerve decompression) and after
facial trauma (nasal and cheek bones). Also, larger regions
with a diffusely increased uptake are not necessarily
pathological. Craniofacial sutures and growth centres (such
as the clivus) have diffusely enhanced
18F-fluoride uptake,
congruent to the objective measurements.
PET activity in the petrous bone region is confirmed by
clinical findings. Facial nerve palsy and vestibulocochlear
nerve impairment generally occur in the first 30 years of
life due to impingement of the nerve at the level of the
internal auditory canal, where increased PETactivity is then
observed. Along with the lifetime progression of hyper-
ostosis, one would expect progression to total facial
paralysis and deafness. Typically, the PET activity in this
region surrounding the internal auditory canal decreases,
explaining why the clinical symptomatology remains
stable (Fig. 7).
Clinical application of
18F-fluoride PET/CT for HCI
and bone metabolic disorders in general
In studies using
18F-fluoride there is limited experience
with SUV in spite of the advantages and proven reliability
[16, 17]. Uchida et al. demonstrated differences in SUVs in
the lumbar spine after alendronate treatment in osteoporosis
patients [21]. Reference SUV scores of different areas of
normal bone with this tracer are scarcely described in the
literature. No other studies were found with a detailed
description of average uptake values of unaffected bone in
different anatomical sites.
CT scanning will remain the gold standard for the
diagnosis of HCI because of its high resolution. However,
there is a need to quantify the disease activity rather than to
perform sequential CT scans. This study confirms that
18F-
fluoride PET/CT is a very sensitive imaging technique in
determining disease activity, showing differences in small
population sizes. The indolent character of this metabolic
disorder raises an important limitation: there is a narrow
window between normal and pathological metabolic activ-
ity. Therefore, SUV measurements should always be
accompanied with the visual interpretation of changing
bone activity patterns over time in different regions.
Age is the most important covariate to take into account
in regions with a high bone turnover (i.e. sphenoid and
clivus area) as osteoblastic activity diminishes with increas-
ing age resulting in a lower uptake of
18F-fluoride [20]. In
this study we had difficulties finding young individuals to
serve as appropriate control subjects. This caused an
unequal age distribution in the different groups and was
Table 3 Hot spots found in HCI patients
Location SUVmean SUVmax
Frontal bone, skull base 6.49 7.25
7.78 9.47
8.60 9.85
8.68 9.94
9.24 10.69
11.94 13.63
12.91 15.61
Frontal bone, skullcap 4.77 6.45
7.57 8.78
7.82 9.09
12.44 13.73
Occipital suture 7.40 8.82
7.59 9.05
8.03 9.24
8.74
a 11.24
a
9.09
a 11.71
a
The paired SUVmean and SUVmax represent one hot spot in one patient
aResults from the same patient
892 Eur J Nucl Med Mol Imaging (2011) 38:884–893therefore potentially one of the most serious drawbacks of
this study. To overcome this, group 2 (non-affected family
members) with a similar age distributionasgroup 1 servedasa
secondarycontrolgroupandshowedsimilarresultsasgroup3.
Thisstudyusesthesemi-quantitativeSUVratioforthefirst
time in a case-control study. The use of a consistent internal
control site is important as an internal validation check of
correct SUV processing.
18F-Fluoride PET/CT, analysed by
SUV, appears to be reliable since we found differences
supporting our hypotheses. If the aforementioned limitations
are taken into account, the combination of SUV measure-
ments and visual interpretation can be of important value and
might bring
18F-fluoride PET/CTcloser to being a diagnostic
test for metabolic bone diseases.
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